Efficacy and Safety of Carvedilol in Cirrhosis Patients With Uncomplicated Ascites Without High Risk Esophageal Varices
A legfontosabb adatok
- Ki végzi
- Institute of Liver and Biliary Sciences, India
- Hol
- India1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 104 fő vett részt
- Kezdés
- 2021. okt. 1.
- Befejezés
- 2023. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Carvedilol
- Standard Medical Treatment
- A regiszteradat frissítve
- 2025. március 20.
Ki vehet részt
- Életkor
- 18 év – 65 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 22 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18-65 years
- Liver cirrhosis
- Grade II-III high SAAG ascites
- Small low risk or no esophageal varices
- CTP 7-12
Ki nem vehet részt
- AKI at enrollement (Prior transient volume responsive AKI stage I included)
- Post renal or liver transplantation
- Prior intolerance or S/E to carvedilol or diuretics
- History of CAD, PVD, ventricular arrythmia, Bronchial asthma
- Bilirubin >5 mg/dl
- Age <18 years
- SBP at diagnosis
- Severe Hyponatremia (Na <125 MEq/L)
- Grade II/III/IV HE
- Advanced HCC (BCLC C,D), PVTT, Pregnancy or Lactating mother
- High risk varices (Large varices or small high risk varices)
- CTP >12
- ACLF
- Mixed / TB ascites
- Known CKD, obstructive uropathy
- Patient on MV, NIV, systemic sepsis and shock
- Lack of informed consent
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The cumulative risk of refractory ascites is in the order of 20% within five years of the development of ascites. An elevated sinusoidal pressure is essential for the development of ascites, as fluid accumulation does not develop at portal pressure gradient below 8 mm Hg, and rising corrected sinusoidal pressure correlates with decreased 24-hour urinary excretion of sodium.More recently, it has been hypothesised that bacterial translocation associated with portal hypertension in cirrhosis and related pathogen-associated, molecular pattern activated innate immune responses lead to systemic inflammation.This is associated with vasodilatation as well as release of proinflammatory cytokines, reactive oxygen and nitrogen species, contributing to organ dysfunction.This activates sympathetic nervous system stimulating reabsorption of sodium in proximal,distal tubules, loop of Henle and collecting duct as well as the renin-angiotensin-aldosterone system, leading to sodium absorption from distal tubule and collecting duct.[5]Renal sodium retention and eventual free water clearance due to non-osmoticrelease of arginine-vasopressin and its action on V2 receptor in the collectingduct underlie the fluid retention associated with oedema and ascites in cirrhosis.The lowering of portal pressure using non selective beta blocker has also been shown to reduce the development of ascites, refractory ascites and hepatorenal syndrome.Furthermore, the effect of non slective beta blocker on intestinal permeability, bacterial translocation and inflammatory response has been proposed to mitigate the risk of developing spontaneous bacterial peritonitis.
A vizsgálat 2 csoportja
- Carvedilol with Standard Medical TreatmentA vizsgált kezelés
Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP \>90, HR \>55.
Kezelés: Carvedilol és Standard Medical Treatment
- Standard Medical TreatmentMár használt kezelés, összehasonlításként
\- Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Efficacy and Safety of Carvedilol in Cirrhosis Patients With Uncomplicated Ascites Without High Risk Esophageal Varices- A Randomised Controlled Trial"
- Publikációk
- Efficacy and Safety of Carvedilol in Cirrhosis Patients With New-Onset Uncomplicated Ascites Without High-Risk Esophageal Varices (CARVE-AS Trial).The American journal of gastroenterology, 2026
- A regiszteradat frissítve
- 2025. március 20.